Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Pieter Van Remoortere"'
Autor:
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Publikováno v:
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Abstract Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhoti
Externí odkaz:
https://doaj.org/article/61e6a0119abd4699b62cba409899ce21
Publikováno v:
Virology Journal, Vol 14, Iss 1, Pp 1-10 (2017)
Abstract Background In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high su
Externí odkaz:
https://doaj.org/article/b8e56cc302c3411a9f7452c4760b97dc
Autor:
Wim Pierson, Marianne Tuefferd, Florence Herschke, Leen Slaets, Marjolein Crabbe, Dorien Verstappen, Steffi De Pelsmaeker, Ian Strickland, Edward J Gane, Christian Schwabe, Yingjie Zhang, Peter Meerts, Joris Vandenbossche, Pieter Van Remoortere, Inge Verbrugge, An De Creus
Publikováno v:
Antiviral Therapy. 28:135965352311728
Background Chronic hepatitis B (CHB) is responsible for major disease burden worldwide. However, the number of available therapies is limited; cure remains an elusive goal. JNJ-64794964 (JNJ-4964) is an oral toll-like receptor-7 (TLR7) agonist being
Autor:
Bart Fevery, Liviawati S Wu, Rui Li, Leen Slaets, An De Creus, Abbie Oey, Ilham Smyej, Ullrich Schwertschlag, Samia Siddiqui, Pieter Van Remoortere, Christian Schwabe, E.J. Gane, Mina Pastagia, Joris Vandenbossche, Clark Musto
Publikováno v:
Antiviral Therapy. 26:58-68
Background This Phase I, two-part, first-in-human study assessed safety/tolerability and pharmacokinetics/pharmacodynamics of single-ascending doses (SAD) and multiple doses (MD) of the oral toll-like receptor-7 agonist, JNJ-64794964 (JNJ-4964) in he
Autor:
Sushmita Mukherjee Chanda, Christian Schwabe, E.J. Gane, Megha Patel, Oliver Lenz, Jan Snoeys, Jeysen Yogaratnam, Christopher Westland, Jennifer Vuong, Willem Talloen, Thomas N. Kakuda, Pieter Van Remoortere, John Fry
Publikováno v:
Antiviral therapy. 26(1-2)
Background Pharmacokinetics and safety of JNJ-64530440, a hepatitis B virus capsid assembly modulator producing normal empty capsids (CAM-N), in healthy volunteers were evaluated. Methods This Phase I study (NCT03439488) was a double-blind, randomise
Autor:
Liviawati S Wu, Yue Hu, Edward J Gane, Leen Slaets, An De Creus, Yanhua Ding, Junqi Niu, Christian Schwabe, Nele Goeyvaerts, Zhongnan Xu, Dandan Huo, Marianne Tuefferd, Inge Verbrugge, Pieter Van Remoortere, Ullrich Schwertschlag, Joris Vandenbossche
Publikováno v:
Antiviral Therapy. 28:135965352311516
Background JNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)–dependent mechanism, may enhance host immunity suppressed by persistent exposure to hepatitis B antigens in chronic hepatitis B. Methods PK and PD data were pooled from 2 s
Autor:
An De Creus, Leen Slaets, Bart Fevery, Ellen Van Gulck, Linghua Zhou, Tim Van De Parre, Celine Van Den Broeke, Dessislava Dimitrova, Isabelle Lonjon-Domanec, David Bluem, Jr, Pieter Van Remoortere, Stefan Bourgeois, Patrick Kennedy, Sandra De Meyer
Publikováno v:
Journal of Hepatology. 77:S72-S73
Autor:
Ed J. Gane, Christian Schwabe, Elina Berliba, Pisit Tangkijvanich, Alina Jucov, Nelea Ghicavii, Thierry Verbinnen, Oliver Lenz, Willem Talloen, Thomas N. Kakuda, Chris Westland, Megha Patel, Jeysen Z. Yogaratnam, Leonard Dragone, Pieter Van Remoortere
Publikováno v:
The Journal of antimicrobial chemotherapy. 77(4)
Objectives We investigated JNJ-64530440 (a hepatitis B virus capsid assembly modulator) safety, antiviral activity and pharmacokinetics in patients with chronic hepatitis B (CHB) (Phase 1b, NCT03439488). Methods Twenty treatment-naive, HBeAg-positive
Autor:
M. Gamil, Ann Vandevoorde, Veerle Van Eygen, Pieter Van Remoortere, Fred Poordad, Donghan Luo, Eric Lawitz, Julio A. Gutierrez, Greet Beets, Leen Vijgen, Maria Beumont
Publikováno v:
Health Science Reports
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhotic patient
Autor:
Jeysen Yogaratnam, John Fry, Toni Mitchell, Pieter Van Remoortere, Jennifer Rito, Thomas N. Kakuda, Malcolm Boyce, Kusum Gupta, Julian A. Symons, Sushmita Mukherjee Chanda
Publikováno v:
Antiviral Therapy. 23:555-566
Background This double-blind, first-in-human Phase I study evaluated pharmacokinetics, safety and tolerability of AL-794 (prodrug of ALS-033719), a potent endonucle-ase inhibitor of influenza A and B in healthy volunteers. Methods Healthy adult volun